background: Anti-Müllerian hormone (AMH) is an established marker of ovarian reserve and a good predictor of poor or excessive ovarian response after controlled hyperstimulation. However, it is unclear whether it can predict the ultimate outcome of assisted conception, live birth. We undertook a systematic review and meta-analysis to examine whether AMH is a predictor of live birth in women undergoing assisted conception.
Introduction
The age-related decline in oocyte quantity and quality (Nelson et al., 2013b) underpins the decline in success rates and prospect of live birth after assisted conception with advancing maternal age (Oudendijk et al., 2012) . Age alone however is of limited accuracy in predicting live birth; thus there is a need for improved prediction for individualization of counselling. The substantial heterogeneity in the size of the ovarian reserve at any given age (Wallace and Kelsey, 2010) results in marked inter-individual variation in ovarian response despite optimal ovarian stimulation. Analysis of this heterogeneity may provide insights into understanding individual fertility and how it changes with age, and it is also a likely source of clinically useful biomarkers. A variety of ovarian reserve tests have been developed and their predictive capacity for ovarian response examined. In recent systematic reviews, individual patient data meta-analysis and international multicentre trials, antiMüllerian hormone (AMH) has been confirmed as the current best biomarker for prediction of poor and excessive ovarian response Broer et al., 2009 Broer et al., , 2011 Broer et al., , 2013 Nelson et al., 2009; Anckaert et al., 2012) .
Given the strength of the relationships with oocyte yield, the association of AMH with pregnancy after assisted conception has been examined, but results were inconclusive. Some studies have concluded that AMH is not associated with pregnancy van Rooij et al., 2006) while others have found a positive association (Nelson et al., 2007; Honnma et al., 2013) . A recent individual patient data meta-analysis in 1008 patients undergoing fertility treatment demonstrated a weak association of AMH with ongoing pregnancy (Broer et al., 2013) . As live birth is the ultimate outcome of assisted conception, clarification of whether AMH is predictive of this outcome is warranted.
The observational studies that have examined the association of AMH and live birth have either been small (Nelson et al., 2007; Lee et al., 2009; Majumder et al., 2010) or restricted to specific subpopulations of infertility patients (Gleicher et al., 2010; Arce et al., 2013) . To provide an accurate estimate of the effect size we undertook a systematic review and meta-analysis of all eligible studies to examine whether AMH can predict live birth in women undergoing assisted conception.
Methods
This study was conducted according to the PRISMA guidelines (Liberati et al., 2009) and followed a structured protocol established among the authors prior to the start of the literature search.
Eligibility criteria
Studies were included if they met the following criteria: (i) the study population included women of reproductive age undergoing IVF or ICSI, with any stimulation protocol; (ii) serum AMH was measured in all study participants before ovarian stimulation; (iii) the clinical outcome of live birth was recorded for all participants; and (iv) any study design except case reports. Thus, studies referring to intrauterine insemination were excluded as were studies referring to on-going pregnancy rate but not live birth rate. Studies referring to follicular fluid AMH or oocyte donation programmes were excluded. Our search included studies published up to August 2013 and there was no language restriction.
Search
The following electronic databases were searched: PubMed, Embase, Medline, Web of Knowledge and the Cochrane trial register. Search terms for live birth (MeSH; live birth, ongoing pregnancy, pregnancy) and key words 'anti-müllerian hormone', 'müllerian-inhibiting substance', or 'müllerian-inhibiting factor' were combined with a search filter for studies related to humans. The abstracts of all studies identified were screened by two researchers (S.I. and S.M.N.). Any studies including data on AMH and live birth or other assisted conception outcomes were read in full. The reference lists of the selected papers were hand-searched in order to identify potentially relevant papers. Grey literature was also searched via the opengrey website.
Study selection and data collection
Subsequently, two researchers (S.I. and S.M.N.) carefully read and independently judged all selected articles. If a study fulfilled the eligibility criteria, it was included in the systematic review. If the study provided extractable information about a cut-off of AMH which was associated with a higher or lower chance of live birth or the sensitivity, specificity or area under the curve (AUC) of the receiver operating characteristic curve of AMH in predicting the chance of live birth, it was selected for the meta-analysis. Any disagreement between the two researchers was resolved with discussion. If a study was selected for the systematic review but did not provide data that could be included in the meta-analysis, the authors were contacted via email. If the authors did not reply or the relevant information was not available, the studies were not included in the meta-analysis. If the authors did not provide the information asked, but the relevant information was extractable using a reverse engineering technique through Plot digitizer, a computer software programme which can extract data from published plots, the articles and data therein were used in the meta-analysis.
For each study the first author, year of publication, number of cycles, number of patients, stimulation protocol, mean/median age of the patients, suggested cut-off point of AMH (converted to ng/ml using the conversion formula ng/ml ¼ 7.14 pmol/l), AMH assay, number of live births among Anti-Müllerian hormone and live birth the patients with low or high serum AMH (below or above the cut-off point), study design and patient selection were extracted.
Quality appraisal of the selected studies
Each selected study was further assessed according to the QUADAS 2 checklist to assess the risk of bias and the applicability of primary diagnostic accuracy studies (Whiting et al., 2011) . It consists of four main domains testing the risk of bias (low, high or unclear) in patient selection, index test, reference test and flow of each study.
We tried to minimize the risk of publication bias by a comprehensive search strategy which included unpublished (grey) literature. The risk of publication bias and potential small study effect was visually assessed by constructing a funnel plot which plots estimates of diagnostic accuracy against statistical precision . In addition, we performed a linear regression of log diagnostic ratios on the inverse root of effective sample sizes as a test for funnel plot asymmetry, where a non-zero slope coefficient (P , 0.10) is suggestive of significant asymmetry and small study bias (Deeks et al., 2005) .
Data synthesis and analysis
The statistical analysis was undertaken using the Stata/SE (version 12.1, Stata Corp, USA) and SAS/STAT software. Pooling of the data related to the number of live births among the study participants with AMH below and above a cut-off point used the random effects model for binary data and provided a summary estimate of diagnostic odds ratio (DOR) and 95% confidence intervals (CI). The DOR summarizes the diagnostic accuracy of the AMH tests and can take values from 0 to infinity. It expresses the odds of detecting AMH above a cut-off point (positive test result) among women with live births relative to the odds of detecting AMH above the cut-off among women without live births (Glas et al., 2003) .
Heterogeneity resulting from true diagnostic accuracy not being identical in each study was quantified by the I-squared measure (Higgins et al., 2003) . Sensitivity analysis was performed for studies with similar study populations (women with unknown ovarian reserve versus women with reduced ovarian reserve) to assess whether the DOR varies according to patients' characteristics. In addition, the summary ROC curve, sensitivity, specificity, positive and negative likelihood ratio of AMH for predicting live birth was generated. This was conducted by fitting a two-level mixed logistic regression model, with independent binomial distributions for the true positives and true negatives restricted to the sensitivity and specificity in each study, and a bivariate normal model for the logit transforms of sensitivity and specificity between studies (Rutter and Gatsonis 2001; Reitsma et al., 2005; Harbord et al., 2007) . In addition, the hierarchical model estimated the characteristics of the ROC curve and the adjusted DOR after including age and AMH assay as covariates (Takwoingi and Deeks, 2010) .
Ethics
Formal ethics approval was not required because this analysis consists of pooling of published studies.
Results

Search results
The systematic search of the biomedical databases produced 595 hits; after excluding duplicates 361 citations were identified (Fig. 1) . Unpublished literature (open grey website or hand searching of references) meeting the search indices was not identified. After excluding articles based on the title or abstract, 47 articles were assessed fully for eligibility. Thirty studies were excluded with a reason recorded (Supplementary data, Table SI); thus 17 studies were selected for the systematic review (Nelson et al., 2007; Lee et al., 2009; Gleicher et al., 2010; Majumder et al., 2010; Wang et al., 2010; Friden et al., 2011; La Marca et al., 2011; Weghofer et al., 2011; Grzegorczyk-Martin et al., 2012; Arce et al., 2013; Brodin et al., 2013; Khader et al., 2013; Li et al., 2013; Lin et al., 2013; Lukaszuk et al., 2013; Merhi et al., 2013; Mutlu et al., 2013) . Four of these were excluded from the meta-analysis as extraction of relevant data was not possible even after contacting the authors (Wang et al., 2010; Weghofer et al., 2011; Lin et al., 2013; Mutlu et al., 2013) and a subgroup of another study for the same reason (Lee et al., 2009) . Most of the data from one of the excluded studies (Weghofer et al., 2011) were included in a previous study from the same research group (Gleicher et al., 2010) which contributed to the meta-analysis. One of the studies was in French (Grzegorczyk-Martin et al., 2012) . The characteristics of the studies included in the meta-analysis are listed in Table I .
Pooled estimates
We present data of 6856 cycles (6306 women) undergoing IVF or ICSI. The studies were categorized into those including only women with expected low ovarian reserve (n ¼ 542 women) and those with women with unknown ovarian reserve (n ¼ 5764) to minimize the between study heterogeneity. The pooled DOR for AMH predicting a live birth among women with unknown ovarian reserve who present to a fertility clinic was 2.39 (95% CI: 1.85 -3.08) (Fig. 2a) . The estimated I-squared was 58.9%, suggesting moderate heterogeneity between the studies. After adjustment for age, the DOR obtained by a hierarchical logistic regression model analysis was very similar at 2.48 (95% CI: 1.81 -3.22). After adjusting for the assay used to measure AMH, the DOR was almost identical at 2.42 (95% CI: 1.86-3.14). The DOR for women with expected low ovarian reserve was 4.63 (95% CI: 2.75 -7.81) (I-squared 0%), with wider CIs due to the small number of pooled studies (Fig. 2b) . Hierarchical logistic regression analysis was not conducted for this subgroup of studies because of the small sample size (n ¼ 3 studies). Since the 95% CIs of the DOR of the sensitivity analysis overlapped, the pooled DOR for all studies was estimated at 2.63 (95% CI: 2.02 -3.40) with estimated I-squared of 62.1%. After adjustment for age the DOR for all studies was 2.67 (95% CI: 2.06 -3.48). After including AMH assay as a covariate, the adjusted DOR obtained by the hierarchical model was 2.66 (95% CI: 2.06 -3.43).
For the prediction of live birth in women with unknown ovarian reserve (n ¼ 10 studies), the hierarchical summary receiver operating characteristics (HSROCs) along with study-specific estimates are plotted in Fig. 3 . The parameters of the plot did not change substantially after including age or AMH assay as covariates (data not shown). The summary ROC and 95% CIs do not cross the line of no-discrimination. The AUC was 0.61 (CI 0.56-0.65). The overall summary estimates of the above 10 studies for serum AMH and live birth were sensitivity of 83.7% (95% CI: 72.5-90.9%) and specificity of 32.0% (95% CI: 21.6-44.6%) with adjusted for age sensitivity of 83.7% (95% CI: 72.5-90.1%) and specificity of 32.6% (95% CI: 21.8-45.5%). However, caution is required interpreting the summary sensitivity and specificity as the pooled studies have similar but not identical AMH thresholds (Table I) , and summary sensitivity and specificity can vary according to the threshold used. The adjusted for age positive likelihood ratio was 1.24 (95% CI: 1.14-1.36) and negative likelihood ratio 0.5 (95% CI: 0.39-0.65).
Study quality assessment and publication bias
The quality assessment of the selected studies is represented as percentage of high, low or unclear bias in each domain assessed by the QUADAS 2 tool (Supplementary data, Fig. S1 ). Most studies reported live birth per cycle (or per patient if they included solely the first stimulated cycle (Nelson et al., 2007; Lee et al., 2009; Majumder et al., 2010; La Marca et al., 2011; Grzegorczyk-Martin et al., 2012; Khader et al., 2013) , one study reported live birth per ovum retrieval (Friden et al. 2011) and two reported the cumulative live birth rate (Arce et al., 2013; Li et al., 2013) . The majority of the studies measured AMH using the Diagnostic Systems Laboratories Inc. (DSL, Webster, TX, USA) assay (Nelson et al., 2007; Lee et al., 2009; Gleicher et al., 2010; Majumder et al., 2010; Friden et al., 2011; Brodin et al., 2013; Khader et al., 2013; Lukaszuk et al., 2013; Merhi et al., 2013) with the remainder using the Immunotech-Beckman Coulter (IBC, Marseille, France) assay Grzegorczyk-Martin et al., 2012) or the Beckman Coulter Generation II assay (Arce et al., 2013; Li et al., 2013) . With respect to potential selection bias, two studies excluded women with polycystic ovary syndrome (La Grzegorczyk-Martin et al., 2012) , one excluded couples with severe male factor infertility (La , some studies included only women with low expected ovarian reserve defined either by advanced age and/or high FSH and/or low AMH (Gleicher et al., 2010; Friden et al., 2011; Weghofer et al., 2011; Merhi et al., 2013) .
The funnel plot (Supplementary data, Fig. S2 ) visually suggests asymmetry raising the possibility that studies with small sample size and results lacking statistical significance may be missing; however, the statistical test for funnel plot asymmetry did not reach statistical significance (P ¼ 0.25) .
Discussion
This meta-analysis of 6306 women suggests that AMH has some association with predicting live birth in women undergoing IVF; however, its predictive accuracy is poor. The pooled DOR among 5764 women with unknown ovarian reserve was 2.48 after adjusting for age. In the remaining women with expected low ovarian reserve (n ¼ 542), AMH had a better, albeit still small, predictive effect (DOR ¼ 4.63); however, this needs to be substantiated in larger studies. Although the DOR was greater than unity in all the pooled studies, it was consistently low; it is known that useful tests with good predictive accuracy tend to have DOR above 20 (Fischer et al., 2003) . The HSROC model and 95% CIs of the pooled data did not cross the no-discrimination line, indicating that AMH has some value in predicting live birth. In addition, the prediction 95% confidence region, which suggests the confidence region for a forecast of the true specificity and sensitivity in a future study, includes the line of no-discrimination, if only marginally; this raises the possibility of a positive predictive value of AMH being found in future studies. However, it is established that tests with likelihood ratios ranging from 0.33 to 3 rarely change clinical decisions (Jaeschke et al., 1994) ; therefore, the small positive (1.24) and the large negative likelihood ratio (0.5) found in our study indicate that AMH alone is unlikely to alter a clinical decision based on the chance of live birth after IVF/ICSI. The potential value of ovarian reserve tests, including AMH, in predicting the likelihood of pregnancy after assisted conception has been contentious. Initial meta-analysis and more recent individual patient data meta-analysis did not demonstrate an association Broer et al., 2013) . This was despite ovarian reserve tests, and in particular AMH, being strongly associated with ovarian response and oocyte yield (Broer et al., 2009 (Broer et al., , 2011 (Broer et al., , 2013 , which is a known major determinant of live birth (Sunkara et al., 2011) . The current meta-analysis has used a solid methodology by pooling a large number of studies with the outcome of live birth rather than pregnancy, so the conclusions should not be viewed as contradictory but supplementary.
AMH may not be associated with a positive pregnancy test or ongoing pregnancy, with the small association with live birth only becoming apparent after non-continuing pregnancies are lost. Although we did not test the value of AMH in predicting non-continuing pregnancies or ongoing pregnancies in the current review, we could consider this as a possible biological explanation. This would suggest that AMH is not only a marker of ovarian response and oocyte quantity (La Marca et al., 2010; Broer et al., 2011 Broer et al., , 2013 Arce et al., 2013) , but also that it has a (limited) association with oocyte quality. The decline in oocyte quality with increasing age is well established (Nybo Andersen et al., 2000) , but the literature on ovarian reserve tests and oocyte quality is inconsistent. The positive association of AMH with increasing cumulative live birth rate is attributed to the greater availability of oocytes and embryos and not better oocyte quality by some (Arce et al., 2013) but was found to be independent of age and oocyte yield by others (Brodin et al., 2013) . Several studies have not observed an association between AMH and oocyte or embryo quality (Smeenk et al., 2007; Lie Fong et al., 2008; Guerif et al., 2009; Mashiach et al., 2010; Riggs et al., 2011; Anckaert et al., 2012; Kedem-Dickman et al., 2012; Arce et al., 2013) , whereas others report a positive association (Ebner et al., 2006; Majumder et al., 2010; Irez et al., 2011; Brodin et al., 2013; Lin et al., 2013) . As assessment of oocyte and embryo quality has largely focused on morphology rather than objective measures of euploid status and developmental potential (Plante et al., 2010; Kline et al., 2011) , the alternative outcome of a live birth has been used by some researchers to assess oocyte quality. Many of these studies were small (Ebner et al., 2006; Smeenk et al., 2007; Lie Fong et al., 2008; Majumder et al., 2010; Mashiach et al., 2010; Irez et al., 2011; Riggs et al., 2011; Kedem-Dickman et al., 2012; Lin et al. 2013) , raising the possibility of a beta (false negative) error (Riggs et al., 2011) . The present analysis indicates that AMH has some value, albeit with poor accuracy, in predicting live birth, and that this relationship is independent of age or AMH assay. While most circulating AMH derives from small antral follicles (Weenen et al., 2004; Jeppesen et al., 2013) , AMH expression persists in the cumulus cells surrounding the oocyte at the time of ovulation (Salmon et al., 2004) providing a potential basis for a relationship with oocyte quality distinct from its relationship with follicle number.
The included studies in our analysis reported AMH according to the IBC, the DSL or the Beckman Coulter Generation II assay. Although the IBC and DSL assays differ both in their pairs of monoclonal antibodies and standardization so do not give comparable values, the conversion formula of the DSL assay data into IBC values of 2.02 * DSL ¼ IBC has been used consistently for data aggregation studies (Hehenkamp et al., 2006) . In contrast, the Generation II assay was recently released after harmonization of the other two assays by incorporating the antibodies used in the DSL assay but being calibrated to the Immunotech assay and thereby anticipated to give equivalent values . However, since the commercial release of the AMH Generation II assay it has been demonstrated that there is a systematic shift in assay calibration and AMH values generated with the AMH Generation II assay were significantly lower compared with the DSL assay for women Anti-Müllerian hormone and live birth of similar age (Nelson et al., 2013a) . Therefore, the different AMH assays with the current calibration concerns could be a source of significant heterogeneity in our pooled analysis; however, after adjustment for AMH assay the DOR for both women of unknown ovarian reserve and all women was only changed modestly confirming further that, irrespective of the assay, measured AMH has some value in the prediction of live birth.
Clinical application
The immediate clinical implication of the present finding is that AMH independently of age provides additional information for couples considering assisted reproduction. However, its diagnostic accuracy in live birth is poor and should not be used to alter clinical decisions and exclude couples from IVF/ICSI based on a low AMH. In addition, these data do not justify adoption of an AMH threshold for access to such treatments and further studies are needed to investigate whether a universal AMH threshold is possible, or appropriate.
To date a wide range of prediction models has been developed to facilitate prognostication of the likelihood of success after assisted conception, with none of these going through the three classical phases of model development (Nelson and Lawlor 2011; van Loendersloot et al., 2013) . A recent systematic review and meta-analysis which analysed nine predictive factors in IVF identified that female age and baseline FSH were inversely associated with the likelihood of success after IVF (van Loendersloot et al., 2010) . As AMH is a stronger associate of ovarian reserve than FSH Hansen et al., 2011) , this suggests that future prediction models should consider AMH as an alternative covariate. Critical assessment of whether inclusion of AMH improves the prediction characteristics of existing models, when compared with updating existing prediction models with adjustment or recalibration to account for local circumstances, will be a critical step in confirming its clinical utility in prediction of live birth.
Strengths and limitations
This is the first study presenting pooled data of a large number of cycles to assess the predictive value of serum AMH in live birth after IVF/ICSI. The strengths of the review lie in the extensive search strategy, adherence to recent guidelines (Cochrane 2011), inclusion of non-English studies and robust statistical analysis in accordance with established guidance for diagnostic tests (Irwig et al., 1994; Khan et al., 2001) . Although the process of systematic literature review and meta-analysis is a robust way of generating a more powerful estimate of true-effect size with less random error than individual studies, it does have limitations and the inferences assumed by the data are subject to the limitations and bias of the primary studies. Heterogeneity of the studies must be addressed as it may affect the justification for pooling the data into one analysis. In the case of the present meta-analysis, heterogeneity may have been caused by different baseline characteristics in study participants, different stimulating protocols, variation in the AMH threshold and assay across different studies and study quality characteristics. However, the statistical estimation of heterogeneity was within acceptable levels for pooling studies. In addition, one of the advantages of the HSROC analysis is that it takes into account the full range of variation in the data, differentiating within study from between study variability and systematic from random variability (Gatsonis and Paliwal 2006) . Secondly, our pooled analysis did not include data from some studies (Wang et al., 2010; Lin et al., 2013; Mutlu et al., 2013) and from a subgroup from another study (Lee et al., 2009 (Lee et al., ) (overall n ¼ 1956 as the data to conduct a 2 × 2 table were not extractable or available even after contacting the authors, which we acknowledge may have introduced bias. The largest of these studies showed a positive relationship between AMH and live birth although it attenuated after age stratification (Wang et al., 2010) , while the others did not show an association possibly due to small sample number (n ¼ 83 (Lin et al., 2013) ; n ¼ 213 (Lee et al., 2009) ; n ¼ 192 (Mutlu et al., 2013) ). Also, while the funnel plot analysis raises the possibility that small studies showing non-significant or negative association between AMH and live birth may be missing, an asymmetrical funnel plot does not prove a specific type of bias and may indicate small study effect, i.e. smaller studies have the tendency to inflate the summary effect and moreover, the apparent funnel asymmetry was not statistically significant. Our methodology tried to minimize the possibility of publication bias by implementing a robust search technique without language limitations and by contacting the authors when the relevant information was not extractable. In addition, the qualitative assessment of the included studies indicates that the majority of the studies had low risk of methodological bias (Supplementary data, Fig. S1 ). Our pooled analysis does not derive a summary diagnostic threshold for AMH, as this would be inappropriate due to the individual studies utilizing diverse populations with different fertility potentials and ethnic backgrounds, different AMH cut-off points and different AMH assays.
Conclusion
Based on the current evidence, we found that AMH adds some value in predicting live birth, and this is independent of age or AMH assay. Although the CIs of the DOR for AMH do not cross unity, its predictive accuracy is poor and should not be over-interpreted. These findings were consistent across all of the studies examined, but the existing evidence would be inappropriate to determine a widely applicable threshold value due to the heterogeneity between studies, and likewise to derive the relative risks of live birth across the clinically relevant range of AMH values or exclude women from IVF/ICSI. This evidence can only be obtained by prospectively designed studies of test accuracy with adequate clinical size and attention to limiting bias and appropriate outcome measures (possibly including cost effectiveness analysis) using a decision tree model. This will allow the trade-off between positive and negative benefits to be truly evaluated.
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